Table 3.
Comparison between anti-MCV positive and negative RA patients at study endpoint.
| Anti-MCV +ve (n = 51) mean ± SD | Anti-MCV −ve (n = 13) mean ± SD | 2-tailed significance (P<) | |
|---|---|---|---|
| Age (years) | 42.32 ± 11.57 | 40.12 ± 11.5 | 0.992 |
| DD (years) | 5.91 ± 3.25 | 4.61 ± 2.32 | 0.453 |
| ESR (1st h) | 48.77 ± 11.25 | 28.46 ± 10.54 | 0.001* |
| CRP (mg%) | 21.80 ± 29.83 | 9.0 ± 3.05 | 0.035* |
| DAS-28 | 4.24 ± 1.14 | 2.82 ± 0.35 | 0.05* |
| VAS/100 mm | 61.45 ± 11.40 | 55.76 ± 9.54 | 0.901 |
| SEN score | 20.22 ± 8.85 | 9.46 ± 2.78 | 0.05* |
| Flares per year (n =) | 4.15 ± 1.32 | 2.31 ± 0.05 | 0.05* |
| RF titer (U/L) | 59.91 ± 155.7 | 41.69 ± 73.45 | 0.422 |
| Anti-MCV titer (U/L) | 153.62 ± 240.4 | 19.00 ± 5.59 | 0.000+ |
| Axial joints/Chi-square test | 16/51 (31%) | 1/13 (7%) | 0.044* |
+
Significant by welch statistics due to absence of variance homogeneity.